Articles

Lilly licenses Xigris rights to new biotech firm

Eli Lilly and Co. has agreed to license the U.S. marketing rights of its slow-selling sepsis drug Xigris to a newly created local biotech company called BioCritica that will seek to reinvigorate sales of the medication.

Read More

OrthoIndy looks to loopholes for growth

OrthoIndy, the physician practice that owns the Indiana Orthopaedic Hospital, was able to open a new outpatient facility this spring by working around growth restrictions in the 2010 health care reform law. But its choices for further growth are much starker—which is why it’s lobbying to repeal that provision of the law.

Read More

Health insurers lose push to ease rate review

U.S. insurers led by WellPoint Inc. and UnitedHealth Group Inc. failed to get federal regulators to change a rule in the 2010 health-care overhaul that triggers a review of any premium increases exceeding 10 percent.

Read More

Riley Hospital CEO resigns

Dan Fink, who joined Riley Hospital for Children nearly six years ago, will depart Friday. Marilyn Cox will serve as interim president and CEO while Riley conducts a national search for a new leader.

Read More

Growth in drug spending to slow as generics rise

The annual growth rate in spending on drugs may be cut in half over the next five years as people opt for less expensive generic medicines over brand-name treatments, a health-care research group said Wednesday, highlighting the challenge pharmaceutical firms like Eli Lilly and Co. are facing.

Read More

Amylin sues Lilly over drug development deal

Amylin Pharmaceuticals Inc. said Monday it filed a lawsuit against Eli Lilly and Co., accusing the larger drugmaker of breaking their commercialization deal for diabetes drugs by teaming with the German company Boehringer Ingelheim to develop and sell a competing product.

Read More

Zimmer faces new threat to dominance

Warsaw-based Zimmer Holdings Inc. has enjoyed eight years as the giant in the industry of selling knee- and hip-replacement implants to hospitals. But now it faces a challenge from Johnson & Johnson.

Read More